{'fraction_non_alphanumeric': 0.022809123649459785, 'fraction_numerical': 0.0024009603841536613, 'mean_word_length': 5.95, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Budd-Chiari syndrome and severe thrombocytopenia in a patient with Systemic Lupus Erythematosus and Secondary Antiphospholipid Syndrome].

Systemic Lupus Erythematosus (SLE) is a rheumatic autoimmune disease characterized by multisystemic involvement with a variable prognosis. The association with Antiphospholipid Syndrome (APS) occurs in about 36% of the patients, raising additional problems with treatment and monitoring of these patients. The authors report a clinical case of a girl with SLE and APS who represented Budd-Chiari Syndrome and severe thrombocytopenia. The patient had severe thrombotic event and simultaneously a high hemorrhagic risk due to thrombocytopenia. Long-term resolution of the thrombocytopenia was achieved with mycophenolate mofetil. Long-term anticoagulation for thrombosis prophylaxis is required.